Form 4: Apellis Pharmaceuticals Executive Sells Shares to Cover Tax Obligations

Nur Nicholson, Chief Technical Officer of Apellis Pharmaceuticals, sold 3,948 shares of common stock on January 22, 2025, to cover tax withholding obligations related to released Restricted Stock Units.

Summary

• On January 22, 2025, Nur Nicholson, the Chief Technical Officer of Apellis Pharmaceuticals, sold 3,948 shares of the company's common stock.
• The sale was executed at a price of $30.4255 per share.
• This transaction was conducted to cover tax withholding obligations associated with Restricted Stock Units that vested on January 21, 2025.
• Following the transaction, Nicholson directly owns 84,489 shares of Apellis Pharmaceuticals.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to an insider stock sale for tax purposes. It doesn't inherently convey positive or negative sentiment about the company's performance or future prospects.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. This sale is likely related to standard tax obligations and may not reflect a change in the executive's long-term outlook for the company.

Key Dates

Keywords

Apellis Pharmaceuticals, Nicholson Nur, Form 4, insider trading, stock sale, APLS, Restricted Stock Units, tax withholding